When.com Web Search

  1. Ads

    related to: vabysmo generic name price

Search results

  1. Results From The WOW.Com Content Network
  2. Faricimab - Wikipedia

    en.wikipedia.org/wiki/Faricimab

    Faricimab, sold under the brand name Vabysmo (/ v ə ˈ b aɪ z m oʊ / və-BYEZ-mow), is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

  3. List of drugs: V–Ve - Wikipedia

    en.wikipedia.org/wiki/List_of_drugs:_V–Ve

    This multi-page article lists pharmaceutical drugs alphabetically by name. Many drugs have more than one name and, therefore, the same drug may be listed more than once. Brand names and generic names are differentiated by capitalizing brand names. See also the list of the top 100 bestselling branded drugs, ranked by sales.

  4. List of therapeutic monoclonal antibodies - Wikipedia

    en.wikipedia.org/wiki/List_of_therapeutic...

    When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies. Types of monoclonal antibodies with other structures than naturally occurring antibodies.

  5. FDA Approves First Injectable Eye Medicine For Vision Loss ...

    www.aol.com/news/fda-approves-first-injectable...

    Vabysmo is the first and only FDA-approved injectable eye medicine for wet AMD and DME that improves and. The FDA has approved Genentech's, a unit of Roche Holdings AG (OTC: RHHBY), Vabysmo ...

  6. Drugmakers to raise US prices on over 250 medicines starting ...

    www.aol.com/news/drugmakers-raise-us-prices-over...

    The over 250 drug hikes represent an increase from Dec. 29 last year when drugmakers unveiled plans to raise prices on more than 140 brands of drugs. Drug companies are also reducing some prices ...

  7. Roche shares fall on modest 2024 outlook - AOL

    www.aol.com/news/roche-forecasts-return-growth...

    LONDON/FRANKFURT (Reuters) -Roche shares fell more than 4% on Thursday as the market expressed disappointed with the company's more modest than expected 2024 outlook. Sales in 2023 rose 1% when ...